In spite of the Q1 revenue decline, the firm's CEO said Agilent remains well-positioned for long-term growth due to its diversified business.
Myriad finished the three months ended Dec. 31 with $196.6 million in revenues compared to $177.8 million for the same quarter in 2022, beating analysts' average estimate.
The company said it plans to use the funds to accelerate commercialization of its NULISA proteomic technology.
The trial aims to gather evidence for the broad use of MRD testing across cancer types among some 1,200 patients.
Data from the prospective LIQUIK-01 study supported the decision, showing noninferiority to Guardant Health's Guardant360 assay, which was already covered.
The GA-map Sample Collection Kit can inactivate bacteria and viruses and preserve microbial profiles at room temperature for microbiome analysis for weeks.
MolDx extended coverage to ovarian cancer in both the adjuvant and surveillance settings, and to breast cancer in the neoadjuvant setting across all disease subtypes.
The firms said that DiaCarta's laboratory facilities in California will be used to validate the prostate cancer assay for a commercial launch.
The update takes into consideration evidence published since the release of the original guideline and provides new recommendations on how to analytically validate IHC assays.
Last week, readers were most interested in a story about QuidelOrtho letting go of Doug Bryant following disappointing Q4 earnings results.